Medical condition
Cystic Fibrosis
Cystic Fibrosis is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- mannitol (BRONCHITOL) Respiratory system (R05)
- tezacaftor (SYMKEVI) Respiratory system (R07)
- deutivacaftor (ALYFTREK)
- ivacaftor (KALYDECO) Respiratory system (R07)
- levofloxacin (QUINSAIR) Antiinfectives for systemic use (J01)
- colistimethate sodium (COLOBREATHE) Antiinfectives for systemic use (J01)
- tobramycin (PFIZER AUSTRALIA PTY LTD) Antiinfectives for systemic use (J01)
- lumacaftor (ORKAMBI) Respiratory system (R07)
- deutivacaftor / tezacaftor / vanzacaftor (ALYFTREK) Respiratory system (R07)
- brensocatib (BRINSUPRI) Respiratory system (R03)
- crofelemer (MYTESI)
- aztreonam (CAYSTON) Antiinfectives for systemic use (J01)
Latest Cystic Fibrosis news
FDA Approves GeneCorrect: GeneTech's Breakthrough Cystic Fibrosis Therapy
GeneTech's GeneCorrect has received FDA approval, marking a significant advancement in the treatment of cystic fibrosis and improving patient outcomes.
FDA Approves Trikafta for Cystic Fibrosis in Children Ages 2-5
The FDA has approved Trikafta for the treatment of cystic fibrosis in children aged 2 to 5, marking a significant advancement in pediatric care.